GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study

Advanced chondrosarcomas: role of chemotherapy and survival

(2013) A. Italiano et al.   ANNALS OF ONCOLOGY

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy

(2012) N. Penel et al.   ANNALS OF ONCOLOGY

Vismodegib

(2012) C. M. Rudin   CLINICAL CANCER RESEARCH

Small-Molecule Synthetic Compound Norcantharidin Reverses Multi-Drug Resistance by Regulating Sonic Hedgehog Signaling in Human Breast Cancer Cells

(2012) Yu-Jen Chen et al.   PLoS One

Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance

(2011) J. G. van Oosterwijk et al.   ANNALS OF ONCOLOGY

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Chondrosarcoma in the United States (1973 to 2003): An Analysis of 2890 Cases from the SEER Database

(2009) Angela Ylenia Giuffrida et al.   JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME

siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells

(2009) Dae Kim et al.   Molecular Cancer

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Other Endpoints in Screening Studies for Soft Tissue Sarcomas

(2008) J. Verweij   ONCOLOGIST

The Clinical Approach Towards Chondrosarcoma

(2008) H. Gelderblom et al.   ONCOLOGIST